Thomas John Dietz Leap Therapeutics, Inc. (LPTX) insider trading activity

Thomas John Dietz is Director of LEAP THERAPEUTICS, INC.. Currently has a direct ownership of 48,000 shares of LPTX, which is worth approximately $98,399. The most recent transaction as insider was on Dec 26, 2025, when has been sold 35,000 shares (Common Stock) at a price of $1.2 per share, resulting in proceeds of $42,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 48K

n/a 3M change

n/a 12M change

Total Value Held $98,399

Thomas John Dietz Transaction History

Date	Transaction	Value	Shares Traded	Shares Held	Form
Dec 26 2025	SELL Payment of exercise price or tax liability	$42,000 $1.2 p/Share	35,000 Reduced 42.17%	48,000 Common Stock
Dec 26 2025	BUY Exercise of conversion of derivative security	-	83,000 Added 50.0%	83,000 Common Stock

Also insider at

PRTK

Paratek Pharmaceuticals, Inc. Healthcare

Director

EIGR

Eiger BioPharmaceuticals, Inc. Healthcare

TJD